参考文献/References:
[1] Hom RK, Katzenellenbogen JA. Technetiam-99m-labeled receptor-specific small-molecule radiopharmaceuticals:recent developments and encouraging results[J]. Nucl Med Biol, 1997, 24:485~498.
[2] Eckelman WC, Gibson RE. The path from in vitro autoradiography to in vivo autoradingraphy by external imaging[A].Stumf WE(ed):Autoradiography and Correlatie Imaging[M]. New York:Academic Press, 1995. 529~556.
[3] Shi W, Johnston CF, Buchanan KD, et al.Localization of neuroendocrine tumors with 111In DTPA-octreotide scintigraphy(Octreoscan):a comparative study with CT and MR imaging[J]. Q J Med, 1998, 91:295~301.
[4] Rijks LJM, Bakker PJM, van Tienhoven G, et al.Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVB[J]. J Clin Oncol, 1997, 25:2536~2545.
[5] Bonasera TA, O’Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons[J]. J Nucl Med, 1996, 1009~1015.
[6] Johns CS, Bowen WD, Fisher SJ, et al. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1’-piperidinyl) ethyl]-3-[125I]-iodo-4-methoxybenzamide (P[125I]) MBA) forimaging breast cancer[J]. Nucl Med Biol, 1999, 26:377~382.
[7] John CS, Lim BB, Vilner BJ, et al. Substituted halogenated arylsulfonamides:a new class of sigma receptor binding tumor imaging agents[J]. J Med Chem, 1998, 41:2445~2450.
[8] Waterhouse RN, Chapman J, Izard B, et al.Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents:initial studies in mouse tumor models[J].Nucl Med Biol, 1997, 24:587~593.
[9] Johns CS, Lim BB, Geyer BC, et al.99mTc-labeled σ-receptor-binding complex:synthesis,characterization, and specific binding to human ductal breast carcinoma (T47D) cells[J]. Bioconjugate Chem, 1997, 8:304~309.
[10] Eisenhut M, Mohammed A, Miser W, et al. Melano-ma affine Tc-99 m complexes of N-(2-dithylamino-ethyl) benzamides[J]. J Nucl Med, 1999, 40:120P.
[11] Stanley JG, Goldsmith SJ. Receptor imaging:competitive or complementary to antibody imaging?[J]. Semin Nucl Med, 1997, 27:85~93.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[6]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[7]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[8]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[9]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[10]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
[11]邢诗安.叶酸受体及其在肿瘤核医学中的应用[J].国际放射医学核医学杂志,2002,26(6):257.
XING Shi-an.Folate receptor and the application in tumor nuclear medicine[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(3):257.
[12]王雪鹃,张梅颖,林保和.肿瘤血管活性肠肽受体显像[J].国际放射医学核医学杂志,2001,25(2):65.
WANG Xue-juan,ZHANG Mei-ying,LIN Bao-he.Tumor imaging of vasoactive intestinal peptide receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(3):65.
[13]李林,谭天秩.层粘素受体显像[J].国际放射医学核医学杂志,1999,23(6):245.